The Transition from NAFLD to MASLD and Its Impact on Clinical Practice and Outcomes
We read the study by Younossi et al1 with great interest and would like to congratulate the authors for their superb study. Over the last decade, due to changes in lifestyle, there's been a worldwide uptick in metabolic disorders such as obesity and type 2 diabetes, which have directly or indirectly impacted around 37% of the global adult population with non-alcoholic fatty liver disease (NAFLD).2 This condition is also recognized as a leading cause of hepatocellular carcinoma (HCC).3 However, given the insufficient understanding of NAFLD and the potential misconceptions its name may cause, a Delphi conference conducted by multiple societies has proposed renaming NAFLD to metabolic dysfunction-associated steatotic liver disease (MASLD).
Source: Journal of Hepatology - Category: Gastroenterology Authors: Zhenhua Lu, Weiwei Shao, Jinghai Song Tags: Letter to the Editor Source Type: research
More News: Alcoholism | Cancer & Oncology | Carcinoma | Conferences | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Gastroenterology | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Study | Urology & Nephrology